|
05 Apr 2019 |
U.S. FDA Approves IBRANCE® (palbociclib) for the Treatment of Men with HR+, HER2- Metastatic Breast Cancer
|
|
05 Apr 2019 |
Nanobiotix announces first ever radioenhancer to receive European market approval
|
|
05 Apr 2019 |
Fresenius Kabi Receives European Commission Approval For Adalimumab Biosimilar IDACIO
|
|
04 Apr 2019 |
EMA Validates Daiichi Sankyo's Marketing Authorization Application for Pexidartinib for Treatment of Patients with TGCT, a Rare, Debilitating, Non-Malignant Tumor
|
|
04 Apr 2019 |
Inovio's Novel HPV Therapy INO-3106 Demonstrates Clinical Efficacy Against Rare Respiratory Tract Tumors in Pilot Clinical Study
|
|
04 Apr 2019 |
Clinigen K.K. and GC Pharma Announce Exclusive Licensing Agreement in Japan for Hunterase (Idursulfase-beta) ICV, Hunter Syndrome Drug
|
|
04 Apr 2019 |
VIZIMPRO® (dacomitinib) Receives Marketing Authorization in European Union (EU) for the First-Line Treatment of Adult Patients with EGFR-Mutated Non-Small Cell Lung Cancer
|
|
04 Apr 2019 |
Janssen Announces Investigational CAR-T Therapy JNJ-68284528 Granted PRIME Designation by the European Medicines Agency
|
|
04 Apr 2019 |
Further record year of biologics sales in 2018 due to innovative antibodies
|
|
03 Apr 2019 |
Fate Therapeutics Announces First Patient Treated with iPSC-derived NK Cell Cancer Immunotherapy FT500 Successfully Completes Initial Safety Assessment
|
|
03 Apr 2019 |
AACR 2019 Presentations Highlight CX-2009, a First-In-Class Probody Drug Conjugate Targeting Novel Tumor Antigen, CD166
|
|
03 Apr 2019 |
Aptevo Therapeutics Presents New Preclinical Data for APVO436 and ALG.APV-527 at the American Association for Cancer Research 2019 Annual Meeting
|
|
03 Apr 2019 |
Gritstone Oncology Presents Data at AACR Demonstrating MHC Class II Neoantigen Prediction with EDGE™ Significantly Outperforms Current Prediction Methods
|
|
03 Apr 2019 |
Jounce Therapeutics Presents Preclinical Data from JTX-8064 Program at the 2019 American Association for Cancer Research (AACR) Annual Meeting
|
|
03 Apr 2019 |
Agenus Begins Dosing with Next-Gen Anti-CTLA-4 Antibody
|
|
03 Apr 2019 |
Results From Combination of APR-246 with Immuno-Oncology Agents Presented at the 2019 American Association for Cancer Research (AACR) Annual Meeting in Atlanta
|
|
03 Apr 2019 |
Amylyx Pharmaceuticals Announces First Patients Dosed in PEGASUS Phase 2 Trial of AMX0035 in Alzheimer’s Disease and Expansion of the Trial
|
|
03 Apr 2019 |
Xencor and Astellas Enter Collaboration for Novel Bispecific Antibody Program
|
|
03 Apr 2019 |
Clovis Oncology Announces Interim Results from Rubraca® (rucaparib) Phase 2 Study in Advanced Pancreatic Cancer and Nonclinical Data in Multiple Solid Tumor Types for Rucaparib and Lucitanib Presented at AACR 2019
|
|
03 Apr 2019 |
FDA Clears the IND for UCARTCS1, the First Allogeneic CAR-T to Treat Multiple Myeloma Patients
|
